Kairos Pharma (NYSEAMERICAN:KAPA) Given Buy Rating at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Kairos Pharma (NYSEAMERICAN:KAPA) in a research report sent to investors on Tuesday,Benzinga reports. The brokerage currently has a $9.00 price target on the stock.

Kairos Pharma Trading Down 14.1%

Kairos Pharma stock opened at $0.87 on Tuesday. Kairos Pharma has a 12 month low of $0.40 and a 12 month high of $3.25. The stock’s 50 day moving average is $1.30 and its 200-day moving average is $0.97. The company has a market capitalization of $17.99 million, a price-to-earnings ratio of -2.55 and a beta of 2.02.

Institutional Investors Weigh In On Kairos Pharma

An institutional investor recently bought a new position in Kairos Pharma stock. XTX Topco Ltd purchased a new stake in Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 62,746 shares of the company’s stock, valued at approximately $44,000. XTX Topco Ltd owned 0.31% of Kairos Pharma at the end of the most recent quarter.

Kairos Pharma Company Profile

We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.